ES2356883B1 - Composición para el tratamiento del dolor y/o la inflamación. - Google Patents

Composición para el tratamiento del dolor y/o la inflamación. Download PDF

Info

Publication number
ES2356883B1
ES2356883B1 ES200802210A ES200802210A ES2356883B1 ES 2356883 B1 ES2356883 B1 ES 2356883B1 ES 200802210 A ES200802210 A ES 200802210A ES 200802210 A ES200802210 A ES 200802210A ES 2356883 B1 ES2356883 B1 ES 2356883B1
Authority
ES
Spain
Prior art keywords
pain
seq
substituted
unsubstituted
group
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
ES200802210A
Other languages
English (en)
Spanish (es)
Other versions
ES2356883A1 (es
Inventor
Cristina Carreño Serraima
Wim Van Den Nest
Antonio Ferrer Montiel
Mar�?A Camprub�? Robles
Jimena Fern�?Ndez Carneado
Berta Ponsati Obiols
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
BCN Peptides SA
Original Assignee
DiverDrugs SL
BCN Peptides SA
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority to ES200802210A priority Critical patent/ES2356883B1/es
Application filed by DiverDrugs SL, BCN Peptides SA filed Critical DiverDrugs SL
Priority to DK09777419.4T priority patent/DK2318033T3/en
Priority to LTEP09777419.4T priority patent/LT2318033T/lt
Priority to BRPI0911743-1A priority patent/BRPI0911743B1/pt
Priority to ARP090102843A priority patent/AR072610A1/es
Priority to TR2019/00542T priority patent/TR201900542T4/tr
Priority to CN200980137382.XA priority patent/CN102164610B/zh
Priority to SG2013055900A priority patent/SG192548A1/en
Priority to SI200931917T priority patent/SI2318033T1/sl
Priority to HUE09777419A priority patent/HUE042083T2/hu
Priority to JP2011519085A priority patent/JP5920916B2/ja
Priority to CA2731880A priority patent/CA2731880C/en
Priority to EP09777419.4A priority patent/EP2318033B8/en
Priority to PL09777419T priority patent/PL2318033T3/pl
Priority to ES09777419T priority patent/ES2714357T3/es
Priority to PT09777419T priority patent/PT2318033T/pt
Priority to AU2009273471A priority patent/AU2009273471C1/en
Priority to PCT/EP2009/005381 priority patent/WO2010009892A2/en
Priority to MX2011000868A priority patent/MX2011000868A/es
Priority to HRP20190059TT priority patent/HRP20190059T1/hr
Priority to KR1020117004108A priority patent/KR20110056491A/ko
Priority to US13/055,598 priority patent/US20110206752A1/en
Priority to RU2011105280/04A priority patent/RU2515054C2/ru
Priority to IL210810A priority patent/IL210810B/en
Publication of ES2356883A1 publication Critical patent/ES2356883A1/es
Application granted granted Critical
Publication of ES2356883B1 publication Critical patent/ES2356883B1/es
Priority to US16/233,378 priority patent/US20190184054A1/en
Priority to CY191100041T priority patent/CY1121125T1/el
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L15/00—Chemical aspects of, or use of materials for, bandages, dressings or absorbent pads
    • A61L15/16—Bandages, dressings or absorbent pads for physiological fluids such as urine or blood, e.g. sanitary towels, tampons
    • A61L15/42—Use of materials characterised by their function or physical properties
    • A61L15/44—Medicaments
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/1703—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • A61K38/1709—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00—Cosmetics or similar toiletry preparations
    • A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
    • A61K8/64—Proteins; Peptides; Derivatives or degradation products thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/06—Antimigraine agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
    • A61Q19/00—Preparations for care of the skin
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L2300/00—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices
    • A61L2300/20—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices containing or releasing organic materials
    • A61L2300/25—Peptides having up to 20 amino acids in a defined sequence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L2300/00—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices
    • A61L2300/40—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices characterised by a specific therapeutic activity or mode of action
    • A61L2300/402—Anaestetics, analgesics, e.g. lidocaine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L2300/00—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices
    • A61L2300/40—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices characterised by a specific therapeutic activity or mode of action
    • A61L2300/41—Anti-inflammatory agents, e.g. NSAIDs

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Zoology (AREA)
  • Immunology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pain & Pain Management (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Toxicology (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Dermatology (AREA)
  • Birds (AREA)
  • Cell Biology (AREA)
  • Materials Engineering (AREA)
  • Hematology (AREA)
  • Rheumatology (AREA)
  • Marine Sciences & Fisheries (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Cosmetics (AREA)
  • Medicinal Preparation (AREA)
ES200802210A 2008-07-24 2008-07-24 Composición para el tratamiento del dolor y/o la inflamación. Active ES2356883B1 (es)

Priority Applications (26)

Application Number Priority Date Filing Date Title
ES200802210A ES2356883B1 (es) 2008-07-24 2008-07-24 Composición para el tratamiento del dolor y/o la inflamación.
PT09777419T PT2318033T (pt) 2008-07-24 2009-07-24 Composições para o tratamento de dor e/ou inflamação
BRPI0911743-1A BRPI0911743B1 (pt) 2008-07-24 2009-07-24 Uso de um peptídeo
ARP090102843A AR072610A1 (es) 2008-07-24 2009-07-24 Composiciones para el tratamiento del dolor y/o la inflamacion
TR2019/00542T TR201900542T4 (tr) 2008-07-24 2009-07-24 Ağrı ve/veya enflamasyon tedavisi için bileşimler.
CN200980137382.XA CN102164610B (zh) 2008-07-24 2009-07-24 用于治疗疼痛和/或炎症的组合物
SG2013055900A SG192548A1 (en) 2008-07-24 2009-07-24 Compositions for the treatment of pain and/or inflamation
SI200931917T SI2318033T1 (sl) 2008-07-24 2009-07-24 Sestavki za zdravljenje bolečine in/ali vnetja
HUE09777419A HUE042083T2 (hu) 2008-07-24 2009-07-24 Készítmények fájdalom és/vagy gyulladás kezelésére
JP2011519085A JP5920916B2 (ja) 2008-07-24 2009-07-24 疼痛および／または炎症治療のための組成物
CA2731880A CA2731880C (en) 2008-07-24 2009-07-24 Compositions for the treatment of pain and/or inflammation comprising snap-25 peptides
EP09777419.4A EP2318033B8 (en) 2008-07-24 2009-07-24 Compositions for the treatment of pain and/or inflammation
PL09777419T PL2318033T3 (pl) 2008-07-24 2009-07-24 Kompozycje do leczenia bólu i/lub stanu zapalnego
ES09777419T ES2714357T3 (es) 2008-07-24 2009-07-24 Composiciones para el tratamiento del dolor y/o la inflamación
DK09777419.4T DK2318033T3 (en) 2008-07-24 2009-07-24 COMPOSITIONS FOR TREATMENT OF PAIN AND / OR INFLAMMATION
US13/055,598 US20110206752A1 (en) 2008-07-24 2009-07-24 Compositions for the treatment of pain and/or inflamation
AU2009273471A AU2009273471C1 (en) 2008-07-24 2009-07-24 Compositions for the treatment of pain and/or inflammation
MX2011000868A MX2011000868A (es) 2008-07-24 2009-07-24 Composiciones para el tratamiento del dolor y/o la inflamacion.
HRP20190059TT HRP20190059T1 (hr) 2008-07-24 2009-07-24 Pripravci za liječenje boli i/ili upale
KR1020117004108A KR20110056491A (ko) 2008-07-24 2009-07-24 통증 및/또는 염증 치료용 조성물
LTEP09777419.4T LT2318033T (lt) 2008-07-24 2009-07-24 Kompozicija, skirta skausmo ir (arba) uždegimo gydymui
RU2011105280/04A RU2515054C2 (ru) 2008-07-24 2009-07-24 Композиции для лечения боли и/или воспаления
PCT/EP2009/005381 WO2010009892A2 (en) 2008-07-24 2009-07-24 Compositions for the treatment of pain and/or inflamation
IL210810A IL210810B (en) 2008-07-24 2011-01-23 Peptides to treat pain and/or inflammation
US16/233,378 US20190184054A1 (en) 2008-07-24 2018-12-27 Compositions for the treatment of pain and/or inflammation
CY191100041T CY1121125T1 (el) 2008-07-24 2019-01-15 Συνθεσεις για τη θεραπευτικη αντιμετωπιση του πονου και/ή της φλεγμονης

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
ES200802210A ES2356883B1 (es) 2008-07-24 2008-07-24 Composición para el tratamiento del dolor y/o la inflamación.

Publications (2)

Publication Number Publication Date
ES2356883A1 ES2356883A1 (es) 2011-04-14
ES2356883B1 true ES2356883B1 (es) 2012-02-22

Family

ID=41462205

Family Applications (2)

Application Number Title Priority Date Filing Date
ES200802210A Active ES2356883B1 (es) 2008-07-24 2008-07-24 Composición para el tratamiento del dolor y/o la inflamación.
ES09777419T Active ES2714357T3 (es) 2008-07-24 2009-07-24 Composiciones para el tratamiento del dolor y/o la inflamación

Family Applications After (1)

Application Number Title Priority Date Filing Date
ES09777419T Active ES2714357T3 (es) 2008-07-24 2009-07-24 Composiciones para el tratamiento del dolor y/o la inflamación

Country Status (24)

Country Link
US (2) US20110206752A1 (enExample)
EP (1) EP2318033B8 (enExample)
JP (1) JP5920916B2 (enExample)
KR (1) KR20110056491A (enExample)
CN (1) CN102164610B (enExample)
AR (1) AR072610A1 (enExample)
AU (1) AU2009273471C1 (enExample)
BR (1) BRPI0911743B1 (enExample)
CA (1) CA2731880C (enExample)
CY (1) CY1121125T1 (enExample)
DK (1) DK2318033T3 (enExample)
ES (2) ES2356883B1 (enExample)
HR (1) HRP20190059T1 (enExample)
HU (1) HUE042083T2 (enExample)
IL (1) IL210810B (enExample)
LT (1) LT2318033T (enExample)
MX (1) MX2011000868A (enExample)
PL (1) PL2318033T3 (enExample)
PT (1) PT2318033T (enExample)
RU (1) RU2515054C2 (enExample)
SG (1) SG192548A1 (enExample)
SI (1) SI2318033T1 (enExample)
TR (1) TR201900542T4 (enExample)
WO (1) WO2010009892A2 (enExample)

Families Citing this family (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2961510A1 (fr) * 2010-06-17 2011-12-23 Oreal Utilisation comme agent de traitement de la transpiration humaine ; nouveaux derives d'acide amine ; compositions les contenant
ES2385683B1 (es) * 2010-10-18 2013-10-07 Bcn Peptides, S.A. Composiciones para el tratamiento del dolor y/o la inflamación.
DK3415157T3 (da) 2011-10-28 2020-10-19 Neostrata Company Inc N-acyldipeptidderivater og anvendelser deraf
WO2013070808A1 (en) 2011-11-07 2013-05-16 Feng Tian Peptide-based compounds as inhibitors of neurotransmitter secretion
US9687669B2 (en) 2011-11-09 2017-06-27 John Stephan Wearable light therapy apparatus
CA2859915A1 (en) * 2012-01-03 2013-07-11 Ruey J. Yu N-acylpeptide derivatives and their uses
EP2649984A1 (en) 2012-04-13 2013-10-16 Lipotec, S.A. Compounds which inhibit neuronal exocytosis
EP2649983A1 (en) 2012-04-13 2013-10-16 Lipotec, S.A. Compounds which inhibit neuronal exocytosis (II)
ES2660901T3 (es) 2012-04-13 2018-03-26 Lubrizol Advanced Materials, Inc. Compuestos que inhiben la exocitosis neuronal (II)
EP2649985A1 (en) 2012-04-13 2013-10-16 Lipotec, S.A. Compounds which inhibit neuronal exocytosis (III)
DE102014007423A1 (de) * 2014-05-22 2015-11-26 Bitop Ag Zusammensetzung zur Behandlung des Auges
RU2580280C2 (ru) * 2014-07-08 2016-04-10 Общество с ограниченной ответственностью "НИТРОЗДРАВ" Композиция для местного применения для снижения или снятия болевого синдрома
GB201505527D0 (en) 2015-03-31 2015-05-13 Jmedtech Pte Ltd Composition
US20190083809A1 (en) 2016-07-27 2019-03-21 Z2020, Llc Componentry and devices for light therapy delivery and methods related thereto
JP7227903B2 (ja) * 2016-11-30 2023-02-22 ルブリゾル アドバンスド マテリアルズ， インコーポレイテッド 皮膚、毛髪、爪および／もしくは粘膜の処置ならびに／またはケアに有用な化合物
KR102293250B1 (ko) * 2017-09-18 2021-08-26 애니젠 주식회사 활성물질-헥사펩타이드 복합체 및 이를 포함하는 화장료 조성물
EP3691618A1 (en) 2017-10-06 2020-08-12 Foundry Therapeutics, Inc. Implantable depots for the controlled release of therapeutic agents
CN116650732A (zh) 2018-01-08 2023-08-29 铸造疗法股份有限公司 经由治疗剂的控制递送用于治疗腔内癌症的装置、系统和方法
US12458589B2 (en) 2018-05-12 2025-11-04 Foundry Therapeutics, Inc. Implantable polymer depots for the controlled release of therapeutic agents
WO2019224184A1 (en) 2018-05-21 2019-11-28 Ipsen Biopharm Limited Suppression of bone cancer-induced allodynia
ES3060502T3 (en) 2018-06-13 2026-03-26 Acraf Peptides having inhibitory activity on neuronal exocytosis
EP3843710A1 (en) 2018-08-28 2021-07-07 Foundry Therapeutics, Inc. Polymer implants
WO2020182970A1 (en) 2019-03-14 2020-09-17 Om Pharma Sa Process for making stable bacterial extracts and their use as pharmaceuticals
WO2020259447A1 (zh) 2019-06-24 2020-12-30 湖南方升泰医药科技有限公司 金属络合物的新应用
CN116731111A (zh) * 2022-10-14 2023-09-12 深圳市维琪科技股份有限公司 合成肽及其组合物和用途

Family Cites Families (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4179337A (en) * 1973-07-20 1979-12-18 Davis Frank F Non-immunogenic polypeptides
US6974578B1 (en) * 1993-12-28 2005-12-13 Allergan, Inc. Method for treating secretions and glands using botulinum toxin
ATE215832T1 (de) * 1994-05-09 2002-04-15 William J Binder Botulinumtoxin zur reduktion von migraine - kopfschmerzen
US6169074B1 (en) * 1996-03-18 2001-01-02 The Regents Of The University Of California Peptide inhibitors of neurotransmitter secretion by neuronal cells
ES2160485B1 (es) * 1999-04-23 2002-05-16 Lipotec Sa Peptidos inhibidores de la exocitosis neuronal, composiciones cosmeticas y farmaceuticas que los contienen.
US6113915A (en) * 1999-10-12 2000-09-05 Allergan Sales, Inc. Methods for treating pain
US6500436B2 (en) * 2000-01-19 2002-12-31 Allergan, Inc. Clostridial toxin derivatives and methods for treating pain
US6641820B1 (en) * 2000-01-19 2003-11-04 Allergan, Inc. Clostridial toxin derivatives and methods to treat pain
US6464986B1 (en) * 2000-04-14 2002-10-15 Allegan Sales, Inc. Method for treating pain by peripheral administration of a neurotoxin
US6565870B1 (en) * 2000-04-28 2003-05-20 Allergan, Inc. Methods for treating bone tumors
US6423319B1 (en) * 2000-10-04 2002-07-23 Allergan Sales, Inc. Methods for treating muscle injuries
GB0111146D0 (en) * 2001-05-04 2001-06-27 Imp College Innovations Ltd Methods
US6623742B2 (en) * 2001-09-17 2003-09-23 Allergan, Inc. Methods for treating fibromyalgia
US7255866B2 (en) * 2001-09-17 2007-08-14 Allergan, Inc. Botulinum toxin therapy for fibromyalgia
US7071167B2 (en) * 2002-11-13 2006-07-04 L'oreal Use of a combination of components with an inhibitory synergistic effect on calcium channels to prevent or treat wrinkles and fine lines
US6838434B2 (en) * 2003-05-02 2005-01-04 Allergan, Inc. Methods for treating sinus headache
GB2416122A (en) * 2004-07-12 2006-01-18 Ipsen Ltd Botulinum neurotoxin composition
ES2362301T3 (es) * 2005-03-03 2011-07-01 Revance Therapeutics, Inc. Composiciones y procedimientos para aplicaciones tópicas y liberación transdérmica de un oligopéptido.
CN102408470A (zh) * 2005-12-23 2012-04-11 洛桑大学 用作神经递质分泌抑制剂和肌肉松弛诱导物的合成肽
GB0602992D0 (en) * 2006-02-15 2006-03-29 Morvus Technology Ltd Methods, genes and proteins
FR2902341B1 (fr) * 2006-06-16 2011-02-25 Scras Utilisation therapeutique simultanee, separee ou etalee dans le temps d'au moins une neurotoxine botulique, et d'au moins un derive opiace
ES2322882B1 (es) * 2006-10-25 2010-04-22 Lipotec Sa Peptidos inhibidores de la exocitosis neuronal.
KR20090041066A (ko) * 2007-10-23 2009-04-28 성균관대학교산학협력단 신경전달물질 배출을 조절하는 합성 펩타이드

Also Published As

Publication number Publication date
AU2009273471B2 (en) 2014-04-17
EP2318033A2 (en) 2011-05-11
LT2318033T (lt) 2019-02-11
CN102164610A (zh) 2011-08-24
EP2318033B8 (en) 2019-02-27
CY1121125T1 (el) 2019-12-11
AU2009273471C1 (en) 2014-08-21
WO2010009892A2 (en) 2010-01-28
CA2731880A1 (en) 2010-01-28
MX2011000868A (es) 2011-06-09
DK2318033T3 (en) 2019-02-04
HRP20190059T1 (hr) 2019-03-08
SG192548A1 (en) 2013-08-30
BRPI0911743B1 (pt) 2021-11-16
ES2714357T3 (es) 2019-05-28
RU2011105280A (ru) 2012-08-27
KR20110056491A (ko) 2011-05-30
PT2318033T (pt) 2019-01-24
US20190184054A1 (en) 2019-06-20
AR072610A1 (es) 2010-09-08
TR201900542T4 (tr) 2019-02-21
BRPI0911743A2 (pt) 2015-07-07
EP2318033B1 (en) 2018-10-17
WO2010009892A8 (en) 2011-02-24
RU2515054C2 (ru) 2014-05-10
JP5920916B2 (ja) 2016-05-18
AU2009273471A1 (en) 2010-01-28
US20110206752A1 (en) 2011-08-25
CA2731880C (en) 2016-12-13
ES2356883A1 (es) 2011-04-14
IL210810A0 (en) 2011-04-28
IL210810B (en) 2018-04-30
WO2010009892A3 (en) 2010-05-14
SI2318033T1 (sl) 2019-02-28
PL2318033T3 (pl) 2019-04-30
CN102164610B (zh) 2014-04-09
JP2011528678A (ja) 2011-11-24
HUE042083T2 (hu) 2019-06-28

Similar Documents

Publication Publication Date Title
ES2714357T3 (es) Composiciones para el tratamiento del dolor y/o la inflamación
ES2625847T3 (es) Péptidos que inhiben la actividad de receptores activados y su uso en composiciones cosméticas o farmacéuticas
ES2993466T3 (en) Compounds useful for the treatment and/or care of the skin, hair, nails and/or mucous membranes
KR102113998B1 (ko) 피부 및／또는 점막의 치료 및／또는 관리용 화합물 및 미용적 또는 약학적 조성물에서의 이의 용도
JP6470679B2 (ja) ニューロンの開口分泌を阻害する化合物（ｉｉｉ）
KR20120104159A (ko) 근 수축을 억제하는 화합물
JP6316799B2 (ja) ニューロンの開口分泌を阻害する化合物
BR112014025396B1 (pt) Composto, composição cosmética ou farmacêutica, e, uso de um composto
WO2012098281A2 (es) Péptidos moduladores de receptores trp y sus usos
ES2385683B1 (es) Composiciones para el tratamiento del dolor y/o la inflamación.
ES2758991T3 (es) Compuestos para el tratamiento y/o cuidado de la piel y/o membranas mucosas y su uso en composiciones cosméticas o farmacéuticas
BR112014010698A2 (pt) peptídeo, procedimento de preparação de um peptídeo, e, composição cosmética ou farmacêutica

Legal Events

Date Code Title Description
FG2A Definitive protection

Ref document number: 2356883

Country of ref document: ES

Kind code of ref document: B1

Effective date: 20120222

PC2A Transfer of patent

Owner name: BCN PEPTIDES, S.A.

Effective date: 20120905